1 in 5 people worldwide have a hearing loss.
In the UK alone, 86% of those who have a hearing loss are not aware of it, putting these individuals at risk of social isolation and experiencing negative health outcomes, including cognitive decline and dementia, falls, depression, increased number of hospitalization, reduced career prospects and a general decline in quality of life (Reed et al., 2019).
OVER 65% OF ADULTS AGED 60+ YEARS EXPERIENCE HEARING LOSS
PREVALENCE IS DRIVEN BY DEMOGRAPHIC SHIFT TOWARDS THE ELDERLY
EARLY IDENTIFICATION OF HEARING LOSS IS KEY TO EFFECTIVE MANAGEMENT
CURRENT SCREENING TESTS FALL SHORT OF MARKET NEEDS
RISK OF SOCIAL ISOLATION
INCREASES RISK OF DEPRESSION AND ANXIETY
LINKED TO EARLY ONSET OF DEMENTIA
ECONOMIC IMPACT AND LOSS OF EMPLOYMENT
Hearing screening is the most efficient means to address unmanaged hearing loss.
But current tests are notoriously unreliable, leaving as many as 2 out of 10 patients with the wrong diagnosis.
Poor accuracy and sensitivity to background noise in current methods has hindered wider adoption of hearing screening in both public and private healthcare.
Hearing Diagnostics’ technology makes screening more accurate and cost-efficient where it wasn’t previously and enables wider and global adoption of screening.
AUDIMETROID uses a spatial paradigm, wherein the patient listens to spatially-localised sounds, simulated in real-time using headphones and inertia measurement sensors. The patient is instructed to turn their head to face towards the perceived sound direction.
By analysing patient head movements, we can determine which sounds the patient actually heard, and we can do so with greater reliability than has been achievable to-date by previous test paradigms.
To deliver change, takes talent.
To improve lives, takes commitment.
To achieve high-quality innovation, takes determination.
We have a team of carefully selected individuals who are passionate about driving a new era of hearing testing technologies. Our core skillsets include:
Revolutionary Hearing Test Set To Turn Heads With Archangels’ Investment We are delighted to announce that we completed our first funding round lead by Archangels, including Equity Gap and private investors, and welcome our new board members, Charles Sweeney (NXD Chairman), Jaqcui McLaughlin (Investor Director + NXD), and Phil Harris (NXD)! We are looking forward …
Check out our jobs page for details and get in touch with us!
Hearing Diagnostics selected for Unlocking Ambition Cohort 2! We’re absolutely delighted to announce that we’ve been selected to participate in the Unlocking Ambition cohort 2! The programme will accelerate our growth towards ensuring hearing testing becomes more accessible and accurate, ensuring everyone receives care at the earliest opportunity. We’re excited to start the programme and meet …